Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an update.
On May 17, 2025, Dr. Reddy’s Laboratories announced that the USFDA completed a Good Manufacturing Practice (GMP) inspection at their API facility in Middleburgh, New York, from May 12 to May 16, 2025. The inspection resulted in a Form 483 with two observations, which the company plans to address within the stipulated timeline, potentially impacting its compliance and operational processes.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the production of generic medications, active pharmaceutical ingredients (APIs), and proprietary products, focusing on delivering affordable and innovative medicines globally.
Average Trading Volume: 2,109,118
Technical Sentiment Signal: Buy
Current Market Cap: $12B
Learn more about RDY stock on TipRanks’ Stock Analysis page.